This year marks the 350th anniversary of German science and technology group Merck KGaA (MRK: DE), a milestone that will remind the industry and wider world that it is the oldest operating pharma company in existence anywhere.
At the same time, Merck will be challenged to prove its enduring relevance, especially with the Healthcare business that accounts for the vast majority of its research and development (R&D) spend.
"Where we introduce the most powerful innovations, it’s a value proposition that people are not going to ignore, even in cash-strapped markets"
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze